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Abstract
AIM: To assess the expression of selected microRNAs 
(miRNA) in hepatitis C, steatotic hepatitis C, noninfect-
ed steatotic and normal liver tissues.
METHODS: The relative expression levels of miR-21, 
miR-33a, miR-96, miR-122, miR-125b, miR-221 and 
miR-224 were determined in 76 RNA samples isolated 
from 18 non-steatotic and 28 steatotic chronic hepati-
tis C (CHC and CHC-Steatosis, respectively) cases, 18 
non-infected, steatotic liver biopsies of metabolic origin 
(Steatosis) and 12 normal formalin-fixed paraffin-em-
bedded liver tissues using TaqMan MicroRNA Assays. 
All CHC biopsy samples were obtained prior to initiat-
ing therapy. Patients’ serum biochemical values, which 
included glucose, triglyceride, cholesterol, alanine 
aminotransferase(ALT), aspartate aminotransferase 
(AST), gamma-glutamyl-transferase (GGT), alkaline 
phosphatase (AP), were obtained and correlated with 
relative miRNA expression.
RESULTS: When compared with control non-infected 
liver samples, miR-122 and miR-221 levels were re-
duced in CHC-Steatosis (P  < 0.03) and in CHC, CHC-
Steatosis and Steatosis (P  < 0.01). Alternatively, the 
expression of miR-33a and miR-224 were elevated in 
CHC-Steatosis and Steatosis in comparison to control 
tissue (P  < 0.01). The levels of miR-33a and miR-224 
in CHC-Steatosis (P  < 0.02) and miR-224 in Steato-
sis (P  < 0.001) were increased in comparison to CHC 
samples. By contrast, the expression of miR-21 did not 
differ statistically between diseased and normal liver 
samples. Levels of miR-33a correlated negatively with 
serum AST and AP levels in Steatosis as well as with 
necroinflammatory grade in CHC, whereas miR-21 cor-
related positively with AST in Steatosis and displayed 
negative correlation with triglyceride level in CHC-St-
eatosis. In contrast, miRNA levels were not correlated 
with ALT, GGT, cholesterol levels or fibrosis stage.
CONCLUSION: Differences in miRNA expression were 
observed between CHC and steatotic CHC, CHC and 
steatotic liver, but not between steatotic CHC and stea-
totic liver of metabolic origin.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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liver diseases that can progress into hepatocellular car-
cinoma. In the current study, differences were found in 
expression of selected microRNAs in biopsy samples of 
steatotic liver, CHC-infected, and steatotic CHC-infected 
liver, compared to control samples. Interestingly, levels 
of miR-224, which are increased in hepatocellular car-
cinoma, were elevated in both types of steatotic liver 
when compared with normal or CHC-infected only liver 
tissues, and may be an indicator of a precancerous 
state.
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INTRODUCTION
Hepatitis C virus (HCV) infection is a significant health 
care problem worldwide. It is estimated that approxi-
mately 170 million people are infected with HCV[1] and 
3% of  the world’s population is chronically infected with 
this virus[2]. Approximately 70% to 80% of  acute infect-
ed cases will develop into chronic hepatitis C (CHC) due 
to failed elimination of  the virus; nearly 20% of  CHC 
patients develop cirrhosis and 20% of  the cirrhotic cases 
further progress to hepatocellular carcinoma (HCC)[3]. 
Treatment options for CHC include combination of  
pegylated interferon and ribavirin, however, the virus 
still fails to clear in a significant proportion of  treated 
patients[4], which contributes to the numerous liver trans-
plantations worldwide. A new triple therapy regimen 
with protease inhibitors holds great promise as clinical 
trials have ended with a significantly improved percent-
age of  patients reaching a sustained viral response[5].
In addition to cirrhosis, hepatic steatosis is also fre-
quently observed in CHC in approximately 40%-86% 
of  CHC patients depending on the viral genotype[6-9]. 
In cultured Huh7 cells, for example, HCV genotype 3a 
core protein results in the highest level of  triglyceride ac-
cumulation[10,11]. The prevalence of  steatosis in HCV-in-
fected patients is two-folds higher than that observed in 
hepatitis B virus-infected patients, which demonstrates 
a correlation between CHC and nonalcoholic fatty liver 
disease (NAFLD)[12]. Hepatic steatosis occurs when fatty 
acids, delivered either from the circulation or synthesized 
de novo by the liver, exceed the liver’s capacity to me-
tabolize fat by means of  β-oxidation or to secrete fat as 
very-low-density lipoproteins (VLDL). This imbalance 
between delivery of  fat and its subsequent secretion or 
metabolism leads to accumulation of  lipid droplets con-
taining triglycerides and cholesteryl esters, predominantly 
in hepatocytes[13]. In NAFLD, the development of  stea-
tosis is linked to obesity and metabolic disorders such 
as hyperlipidemia, insulin resitance and diabetes[14,15]. In 
addition, steatosis is associated with higher alanine ami-
notransferase (ALT) levels[8].
microRNAs (miRNA) are short RNA molecules con-
sidered to negatively modulate gene expression[16] through 
fine-tuning gene expression involved predominantly in 
development, immunity, differentiation and homeosta-
sis[17]. miRNAs act at the posttranscriptional level and in-
duce translational arrest by binding to the 3’ untranslated 
region (UTR) of  messenger RNAs, leading to a reduc-
tion or blockage of  protein synthesis[18]. In comparison 
to normal homeostatic conditions, altered miRNA ex-
pression has been reported in cancers[19] and in several 
other pathologies including liver diseases[20,21]. Moreover, 
a few miRNAs are already suggested to be potential bio-
markers for HCC and chronic hepatitis B infection[22,23].
In the present study, CHC-infected, steatotic CHC-
infected and NAFLD-based steatotic liver biopsies 
were compared to non-infected, normal liver samples 
to assay differences in the expression of  selected miR-
NAs that previously have been associated with fibrosis 
(miR-21, miR-221), fat metabolism (miR-33a, miR-122) 
and hepatocarcinogenesis (miR-21, miR-122, miR-221, 
miR-224)[24-27].
MATERIALS AND METHODS
Patients
A total of  64 patients were enrolled in this study, from 
which 46 CHC-infected patients (genotype 1/b) were 
hospitalized at the 1st Department of  Medicine at the 
University of  Szeged. These patients were divided into 
two groups (CHC or CHC-Steatosis) according to the 
presence of  steatosis in the liver samples, as diagnosed 
by experienced pathologists. Accordingly, 18 patients 
with CHC but without any apparent signs of  steatosis 
were included in the CHC group, whereas 28 CHC pa-
tients having either mild or severe steatosis were includ-
ed in the CHC-Steatosis group (Table 1). An additional 
18 patients with metabolic steatosis of  varying degrees 
but no HCV infection were selected for the Steatosis 
group from the archives of  the 2nd Department of  Pa-
thology at Semmelweis University. Twelve non-infected, 
normal liver samples served as controls and were ob-
tained from deceased patients after organ donation, just 
prior to ligation of  the abdominal aorta and reperfusion. 
In addition, the following serum biochemical values were 
detected and recorded at the time of  biopsy: glucose, 
triglyceride, cholesterol, ALT, aspartate aminotransfer-
ase (AST), gamma-glutamyl-transferase (GGT), alkaline 
phosphatase (AP). The selected samples were analysed 
retrospectively with permission obtained from the local 
Ethical Committee based on the ethical guidelines of  
the 1975 Declaration of  Helsinki. Antiviral treatment 
had not been initiated before obtaining the liver biopsy 
samples from the CHC patients.
Histology
Liver samples were processed according to routine pa-
thology procedures. Briefly, liver tissues were submerged 
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Table 1  Clinical background of patients enrolled in this study
in 10% neutral buffered formalin (in phosphate-buffered 
saline, pH 7.0) immediately after removal and fixed for 
24 h at room temperature. Following dehydration in an 
ethanol series and xylene, the formalin-fixed samples 
were embedded in paraffin (FFPE samples). Paraffin-
embedded samples were cut into 3 to 5 μm thick sec-
tions and staining with HE as well as with picrosyrius 
red for highlight connective tissue. Histological grade 
and stage were determined using the Ishak scoring sys-
tem[28].
RNA isolation
RNA was isolated from several 3 to 4 μm thick sections 
using the RNeasy FFPE Kit (QIAGEN, Venlo, Nether-
lands) according to the manufacturer’s instructions with 
modification for co-purification of  miRNAs[29]. Traces 
of  genomic DNA were removed using Turbo DNase 
digestion (Ambion of  Thermo Fisher Scientific Inc., 
Waltham, United States).
Reverse transcription and quantitative real time PCR
Expression of  individual miRNAs was determined us-
ing the following TaqMan MicroRNA Assays (Applied 
Biosystems of  Thermo Fisher Scientific Inc.): miR-21 
(ID: 000397), miR-33a (ID: 000424, v9.2 where was 
called miR-33), miR-96 (ID: 000186), miR-122 (ID: 
002245), miR-125b (ID: 000449), miR-221 (ID: 000524) 
and miR-224 (ID: 002099). These selected miRNAs are 
reported to be associated with fibrosis, fat metabolism 
and hepatocarcinogenesis[24-27]. Reverse transcription (RT) 
and quantitative real time PCR (qPCR) were performed 
according to the manufacturer’s instructions. Briefly, the 
RT reaction was carried out using a TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems) in a final 
volume of  7.5 μL containing 10 ng total RNA. qPCR 
was performed using the TaqMan Universal PCR Master 
Mix No AmpErase UNG (Applied Biosystems) in a final 
volume of  10 μL containing 0.65 μL RT product. Am-
plification reactions were run on an ABI PRISM 7000 
Sequence Detection System (Applied Biosystems). Rela-
tive expression was calculated by the 2-∆∆Cq formula, ap-
plying the average Cq value of  miR-96 and miR-125b as 
the most stable reference determined by the NormFind-
er application[30], and normalized to the median ∆Cq 
value of  the normal liver samples.
Statistical analysis
The normalized relative expression data were analyzed 
with a nonparametric Kruskal-Wallis ANOVA and me-
dian test using STATISTICA software, version 9.1 (Stat-
Soft Inc., Tulsa, OK, United States). Correlation analysis 
between miRNA expression and histologic grades or 
serum biochemical values of  patients was performed 
with a nonparametric Spearman rank correlation using 
GraphPad PRISM software, version 5.01 (GraphPad 
Software Inc, La Jolla, CA, United States). A P-value of  
0.05 was set as the threshold for statistical significance.
RESULTS
Differences in miRNA expression
Deregulated miRNA expression was observed in 
the diseased liver samples as compared with normal 
control liver samples. Decreased levels of  miR-221 
were found in CHC, CHC-Steatosis and Steatosis 
samples (1/11-fold, P < 0.0001; 1/8-fold, P < 0.01 and 
1/11-fold, P < 0.0008; respectively) and reduced expres-
sion of  miR-122 was detected in CHC-Steatosis sam-
ples (1/5-fold, P < 0.03) when compared with normal 
liver (Figure 1). In contrast, increased levels of  miR-33a 
and miR-224 were found in CHC-Steatosis (5-fold, P 
< 0.0001 and 5-fold, P < 0.0003; respectively) and Ste-
atosis (4-fold, P < 0.01 and 7-fold, P < 0.0001; respec-
tively) samples in comparison with control normal liver 
samples. The expression of  miR-21 was not statistically 
different between the diseased and normal liver samples. 
Elevated levels of  miR-33a and miR-224 were observed 
in CHC-Steatosis samples compared with CHC samples 
(2-fold, P < 0.02 and 4-fold, P < 0.003; respectively). 
Furthermore, increased miR-224 expression was found 
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CHC CHC-steatosis Steatosis
Age (yr, mean ± SD) 42.1 ± 13.2 39.3 ± 14.9 47 ± 11
Gender 10 males, 
8 females
17 males, 
22 females
9 males, 
9 females
Grade1 G1-1 G1-0 -
G2-2 G2-1
G3-0 G3-3
G4-1 G4-2
G5-4 G5-4
G6-5 G6-5
G7-1 G7-5
G8-2 G8-4
G9-1 G9-2
G10-0 G10-1
G11-1 G11-1
Stage1 S0-1 S0-0 -
S1-3 S1-4
S2-9 S2-12
S3-4 S3-10
S4-1 S4-2
Steatosis grade1 - St0-0 St0-0
St1-12 St1-0
St2-7 St2-1
St3-9 St3-3
St4-0 St4-12
AST (U/L, mean ± SD)    54 ± 262   69 ± 58 54 ± 22
ALT (U/L, mean ± SD)   79 ± 39 114 ± 91 95 ± 43
GGT (U/L, mean ± SD)   39 ± 39     83 ± 123 219 ± 185
AP (U/L, mean ± SD) 119 ± 74   124 ± 100 239 ± 167
Cholesterol 
(mmol/L, mean ± SD)
  4.59 ± 0.84   3.30 ± 1.93 6.23 ± 1.24
Triglyceride 
(mmol/L, mean ± SD)
  0.96 ± 0.51   0.94 ± 0.68 2.31 ± 1.46
1Number of cases for each grade and stage are given. The histologic grade 
and stage were determined according to the Ishak scoring system; 2The 
numerical data are presented as the average ± SD. ALT: Alanine trans-
aminase; AP: Alkaline phosphatase; AST: Aspartate transaminase; CHC: 
Chronic hepatitis C; GGT: Gamma-glutamyl-transferase.
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in Steatosis samples compared with CHC samples (five-
fold, P < 0.001) (Figure 1).
Correlation between miRNA expression, serum 
biochemical values and histology grade
miR-33a levels showed a negative correlation with AP 
and AST values in Steatosis samples and also with the 
histology grade in CHC samples. In contrast, the expres-
sion of  miR-21 correlated positively with AST levels 
in Steatosis samples but showed a negative correlation 
with triglyceride levels in CHC-Steatosis samples (Table 
2). The analyzed miRNA levels displayed no correlation 
with ALT, GGT, cholesterol levels or fibrosis stage in the 
liver disease samples. In addition, a correlation between 
miRNA expression and steatosis grade was not observed 
in either the CHC-Steatosis or the Steatosis group.
DISCUSSION
In HCV infection, it is implied that the pathogenesis 
of  steatosis is linked to both metabolic and viral fac-
tors[12,13,31-33]. HCV has been shown to contribute to st-
eatosis in many ways. The HCV core protein facilitates 
the accumulation of  triglyceride-rich droplets through 
impaired lipid oxidation and inhibits microsomal trig-
lyceride transfer protein activity, which ultimately re-
duces the assembly and secretion of  apolipoprotein 
B-containing VLDL[11,34]. In addition to perturbed fat 
metabolism, fat is reported to be required for the as-
sembly of  new HCVs[35]. In addition, HCV forms 
15346 November 7, 2014|Volume 20|Issue 41|WJG|www.wjgnet.com
10
1
0.1
0.01
0.001
2-
△
△
Cq
Normal             CHC        CHC-steatosis    steatosis
miR-21
100
10
1
0.1
0.01
0.001
2-
△
△
Cq
Normal             CHC        CHC-steatosis    Steatosis
miR-33a
P  < 0.0001
P < 0.01
P < 0.02
10
1
0.1
0.01
0.001
2-
△
△
Cq
Normal             CHC        CHC-steatosis    Steatosis
miR-122
P < 0.03
100
10
1
0.1
0.01
0.001
2-
△
△
Cq
Normal             CHC        CHC-steatosis    Steatosis
miR-221
P  < 0.0008
P < 0.01
P  < 0.0001
100
10
1
0.1
0.01
0.001
2-
△
△
Cq
Normal             CHC        CHC-steatosis    Steatosis
miR-224
P  < 0.001
P  < 0.003
P  < 0.0003
P  < 0.0001
A B
C D
E
Figure 1  Normalized microRNA expression levels detected in liver samples. The horizontal lines indicate the median of the data set. The displayed P values are 
the results of Kruskal-Wallis ANOVA test. The upper dotted line indicates two-fold expressional elevation, the lower dotted line signifies a one-half reduction in expres-
sion. CHC: Chronic hepatitis C; CHC-steatosis: Steatotic Chronic hepatitis C.
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Table 2  Non-parametric Spearman's rank correlation be-
tween serum biochemical values, histology grade and miRNA 
expression levels
lipoviral particles with host lipoproteins and these com-
plexes are enriched in triglyceride, cholesterol, and sev-
eral apolipoproteins. These structures, which resemble 
VLDLs, help the viruses avoid detection by the immune 
system[35]. Furthermore, HCV viral proteins (core, NS2 
and NS4B) may contribute to transcriptional activation 
of  lipogenic genes in hepatocytes, such as SREBPs and 
PPAR-α,γ, contributing to fat accumulation by elevating 
cholesterol biosynthesis and import from the blood and 
by deregulating fatty acid β-oxidation and insulin sensi-
tivity, respectively[12].
It has been shown that low sterol conditions allow 
liver cells to protect themselves from additional sterol 
loss. SREBP-2, a transcription factor, is induced by low 
intracellular cholesterol level and activates lipogenic 
genes[25]. This also induces production of  miR-33a, which 
is co-expressed with SREBP-2 from intron 16 of  the 
SREBP-2 gene. miR-33a protects cells from sterol loss 
by downregulating the ABCA1 transporter needed for 
efflux of  cholesterol to generate high density lipoprotein 
(HDL)[36]. It has also been demonstrated that activation 
of  miR-33a results in reduced insulin signalling, cellular 
β-oxidation and cell proliferation by inhibiting CDK6 
and cyclinD1, leading to cell cycle arrest in G1 phase[36]. 
Therefore, antagonism of  miR-33a has been proposed 
as a therapeutic strategy for treating metabolic syndrome 
and NAFLD[25].
Results of  the present study showing elevated miR-
33a levels in CHC-Steatosis samples as compared with 
CHC, and also in CHC-Steatosis and Steatosis samples 
when compared with normal liver samples are in accor-
dance with previous findings. These findings indicate an 
elevated fat retention in samples having hepatic steatosis. 
The lack of  differences between CHC-Steatosis and 
Steatosis intriguingly suggests that the combination of  
HCV and steatosis does not further increase the level of  
miR-33a. Moreover, miR-33a did not correlate with the 
steatosis stage either in the CHC-Steatosis or Steatosis 
sample groups.
In contrast, the expression level of  miR-122 did not 
differ between the examined liver disease groups and 
decreased expression was observed in CHC-Steatosis 
samples as compared with control liver samples. As in 
the case of  miR-33a, the regulatory function of  miR-122 
is also connected to fat metabolism. It may act indi-
rectly on lipid metabolism as silencing of  miR-122 is 
reported to decrease cholesterol level, VLDL and HDL 
fractions as well as fat accumulation in the liver; a target 
gene involved in fat metabolism, however, is yet to be 
identified[17]. Therefore, the role of  miR-122 in lipid me-
tabolism and the observed decreased expression of  this 
miRNA in CHC-Steatosis samples appears contradic-
tory. However, miR-122 is known to be a liver-enriched 
miRNA, composing 70% of  total miRNAs in normal 
hepatocytes[37]. Upon liver injury, when normal hepato-
cytic activity is compromised[38], miR-122 levels have been 
shown to be decreased. For example, miR-122 expression 
is downregulated in NAFLD[20,21], HCV-infected cases[24] 
and HCC[17]. Accordingly, the observed reduction in 
miR-122 expression further suggests that it likely results 
from reduced hepatocyte activity due to liver injury.
In HCV infection, miR-122 has also been shown to 
bind to HCV RNA at two sites of  the 5’ UTR, which 
promotes replication and stimulates translation in vitro[39]. 
In vivo, however, it is more likely that the role of  miR-122 
binding to the 5’ UTR is to protect HCV RNA from exo-
nuclease degradation, as a correlation between miR-122 
expression and intrahepatic or serum viral load has not 
been identified in vivo[40]. Similarly, our results did not 
demonstrate increased levels of  miR-122 in CHC and 
CHC-Steatosis samples in the presence of  HCV. Further-
more, reduced miR-122 expression could also indicate a 
disease state preceding cancer, as the loss of  miR-122 is 
a frequent finding in HCC and correlates with migration, 
invasion and in vivo tumorigenesis[41].
It is known that downregulation of  a miRNA may 
upregulate target oncogenes, thus promoting tumor 
growth due to stimulation of  proliferation. In contrast, 
upregulation of  a miRNA may prevent expression of  
tumor suppressor genes, which normally function to 
inhibit progression of  the cell cycle[19]. In hepatocar-
cinogenesis, gradual increases in expression of  miR-21, 
miR-221 and miR-224 are reported to occur as the liver 
transitions from normal liver through cirrhosis to fully 
developed HCC[42]. Therefore, we aimed to investigate 
whether CHC and steatosis - diseases that eventually 
lead to HCC - would show an elevated expression of  
these miRNAs. It was interesting to find that the ob-
served levels were quite different: miR-224 was upregu-
lated, miR-221 was downregulated and miR-21 showed 
no change.
miR-224 is reported to be an oncomiR that promotes 
proliferation, migration and invasion in HCC through 
activation of  AKT signaling, and has been shown to 
function in liver carcinogenesis and progression[43]. 
Therefore, the observed elevation of  miR-224 levels in 
CHC-Steatosis and Steatosis samples compared with 
both CHC and normal liver samples may indicate that 
steatotic CHC and steatosis could be disease states with 
molecular changes characteristic of  a precancerous stage. 
It has been suggested that an imbalance in the normal 
miRNA pattern leading to disease onset can be mea-
sured long before the onset of  a cancer[16]. miR-221, also 
a known oncomiR, was found to be elevated in HCC 
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Sample group Histologic or serum 
parameter
Correlating miRNA
CHC Grade miR-33a (P < 0.006; r = -0.7)
CHC-steatosis Triglyceride miR-21 (P < 0.05; r = -0.4)
Steatosis AST miR-21 (P < 0.004; r = 0.8)
miR-33a (P < 0.05; r = -0.7)
AP miR-33a (P < 0.02; r = -0.8)
AP: Alkaline phosphatase; AST: Aspartate transaminase; CHC: Chronic 
hepatitis C; miRNA: MicroRNA.
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and in precancerous stages of  human cirrhotic CHC and 
a nonalcoholic steatohepatitis mouse model[27]. miR-221 
primarily targets tumor suppressors that inhibit the cell 
cycle. In contrast to the observed elevation in miR-224 
levels, the reduced expression of  miR-221 in our liver 
disease samples may indicate that miR-221 is not turned 
on as early in CHC, CHC-Steatosis or NAFLD, although 
increased miR-221 expression has been observed in 
choline and folate-deficient NAFLD animal models[44]. 
The oncomiR miR-21 has been implicated in promoting 
cell proliferation, migration, invasion and tumor growth 
by inducing epithelial-mesenchymal transition through 
the AKT/ERK pathway[45]. miR-21 is often overex-
pressed in cancers, including HCC[27], and in the regener-
ating liver[24]. Upregulation of  miR-21 is also reported to 
be present in human liver biopsies of  obese patients and 
rats that were fed high-fat diets. It has been shown that 
unsaturated fatty acids upregulate miR-21 levels, and this 
in turn downregulates PTEN and causes fatty acids to 
trigger steatosis[46]. In contrast, our results did not reveal 
elevated expression of  miR-21 in the examined liver dis-
ease groups. Variations in individual miR-21 levels have 
already been reported in CHC patients[24] and downregu-
lation of  miR-21 has also been found in obese mice and 
in steatotic cells[47,48].
Interestingly, our analysis revealed negative correla-
tions of  miR-33a expression with AST and AP levels 
and inflammation. A negative correlation was also ob-
served when miR-21 levels were compared with triglyc-
eride levels. Thus, it appears that fat metabolism may be 
influenced by the extent of  necroinflammation in CHC 
and Steatosis samples, most likely through the release 
of  miR-33a from damaged liver cells into serum. In 
addition, high fat is capable of  influencing miR-21-
regulated proliferation where it may affect liver regenera-
tion in CHC-Steatosis. Nevertheless, necroinflammation 
seemed to correlate with the level of  miR-21 in Steatosis 
samples, thus contributing to the stimulation of  pro-
liferation. In support of  this finding, AST levels have 
been reported to correlate with miR-21 in a CCl4 mouse 
model for fibrosis[24].
In conclusion, deregulated expression of  selected 
miRNAs (with the exception of  miR-21) was observed 
in the CHC, CHC-Steatosis and Steatosis groups. The 
levels of  miR-33a and miR-224 were increased in associ-
ation with steatosis when compared with CHC-infected 
and normal livers. Nevertheless, CHC, as a dual effect 
together with steatosis, might also have contributed to 
the elevation of  these miRNAs in the CHC-Steatosis 
group, in which the expression of  miR-122 might be 
reduced for similar reasons. In contrast, the observed 
decrease in the expression of  miR-221 was independent 
of  etiology. Intriguingly, no difference in the expression 
of  selected miRNAs was found between CHC-Steatosis 
samples and steatotic liver samples of  metabolic origin, 
indicating that biological changes caused by steatosis are 
more profound at the molecular and cellular level than 
that of  CHC alone; however further studies are war-
ranted on this topic.
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expression of microRNAs (miRNA) has been reported and there is an intense 
drive to identify miRNAs that could serve as biomarkers to uniquely character-
ize a disease or a disease state. With regard to liver diseases specifically, 
miRNAs have already been proposed as potential biomarkers for hepatocel-
lular carcinoma and chronic hepatitis B infection. In addition, identification of 
miRNAs with altered expression levels and their affected targets will help us to 
understand the processes leading to the disease and to identify potential thera-
peutic targets for treatment.
Innovation and breakthroughs
Altered expression of miRNAs in CHC infection and hepatic steatosis of meta-
bolic origin has been reported. At the miRNA level, however, it is not known 
whether steatotic CHC is closer to CHC or to steatosis, or if it shows a unique 
miRNA expression pattern. Furthermore, the samples obtained in the present 
study were acquired prior to the initiation of therapy, thus providing pure dis-
ease samples for analysis.
Application
The study results presented here suggest that the combined effect of CHC in-
fection and steatosis on miRNA expression may be different from CHC infection 
alone and normal liver tissue but not from hepatic steatosis of metabolic origin. 
This further indicates that biological changes caused by steatosis may be more 
profound than CHC infection alone at molecular and cellular levels.
Terminology
miRNAs are noncoding RNAs that are approximately 20 nucleotides in length 
and are known to interfere with gene expression at the posttranscriptional level, 
usually resulting in prevention of protein synthesis. miRNAs play an important 
role in many cellular processes, such as development, differentiation and 
homeostasis, by fine tuning the expression of genes involved. Thus, it is not 
surprising that their expression is changed in different disease states.
Peer review
This is an interesting study on the role of miRNAs in CHC infection and steato-
sis, in which altered miRNA expression was found in steatotic CHC-infected 
and steatotic liver samples of metabolic origin in relation to CHC infection 
alone. Intriguingly, the levels of analyzed miRNAs were not altered between 
the steatotic CHC-infected and steatotic livers. The results are reflective of true 
disease states as the tissue samples were obtained prior to initiating therapy.
REFERENCES
1 Czepiel J, Biesiada G, Mach T. Viral hepatitis C. Pol Arch 
Med Wewn 2008; 118: 734-740 [PMID: 19202952]
2 Alter MJ. Epidemiology of hepatitis C virus infection. World 
J Gastroenterol 2007; 13: 2436-2441 [PMID: 17552026]
3 Aman W, Mousa S, Shiha G, Mousa SA. Current status and 
future directions in the management of chronic hepatitis C. Vi-
rol J 2012; 9: 57 [PMID: 22385500 DOI: 10.1186/1743-422X-9-57]
4 Moriishi K, Matsuura Y. Exploitation of lipid components 
by viral and host proteins for hepatitis C virus infection. 
Front Microbiol 2012; 3: 54 [PMID: 22347882 DOI: 10.3389/
fmicb.2012.00054]
5 Casey LC, Lee WM. Hepatitis C virus therapy update 2013. 
Curr Opin Gastroenterol 2013; 29: 243-249 [PMID: 23563981 
DOI: 10.1097/MOG.0b013e32835ff972]
6 Khan M, Jahan S, Khaliq S, Ijaz B, Ahmad W, Samreen B, 
Hassan S. Interaction of the hepatitis C virus (HCV) core 
15348 November 7, 2014|Volume 20|Issue 41|WJG|www.wjgnet.com
 COMMENTS
Lendvai G et al . microRNA expression in chronic HCV
with cellular genes in the development of HCV-induced ste-
atosis. Arch Virol 2010; 155: 1735-1753 [PMID: 20842391 DOI: 
10.1007/s00705-010-0797-7]
7 Hwang SJ, Lee SD. Hepatic steatosis and hepatitis C: Still 
unhappy bedfellows? J Gastroenterol Hepatol 2011; 26 Suppl 1: 
96-101 [PMID: 21199519 DOI: 10.1111/j.1440-1746.2010.06542.x]
8 Jármay K, Karácsony G, Nagy A, Schaff Z. Changes in lipid 
metabolism in chronic hepatitis C. World J Gastroenterol 2005; 
11: 6422-6428 [PMID: 16425410]
9 Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Cresta 
E, Venturino V, Risso D, Celle G, Testa R. Steatosis and bile 
duct damage in chronic hepatitis C: distribution and rela-
tionships in a group of Northern Italian patients. Liver 1999; 
19: 432-437 [PMID: 10533803]
10 Hourioux C, Patient R, Morin A, Blanchard E, Moreau A, 
Trassard S, Giraudeau B, Roingeard P. The genotype 3-spe-
cific hepatitis C virus core protein residue phenylalanine 164 
increases steatosis in an in vitro cellular model. Gut 2007; 56: 
1302-1308 [PMID: 17213339]
11 Abid K, Pazienza V, de Gottardi A, Rubbia-Brandt L, Conne 
B, Pugnale P, Rossi C, Mangia A, Negro F. An in vitro mo-
del of hepatitis C virus genotype 3a-associated triglycerides 
accumulation. J Hepatol 2005; 42: 744-751 [PMID: 15826725]
12 Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schus-
ter C. Hepatitis C virus, cholesterol and lipoproteins--im-
pact for the viral life cycle and pathogenesis of liver disease. 
Viruses 2013; 5: 1292-1324 [PMID: 23698400 DOI: 10.3390/
v5051292]
13 El-Zayadi AR. Hepatic steatosis: a benign disease or a si-
lent killer. World J Gastroenterol 2008; 14: 4120-4126 [PMID: 
18636654]
14 Rosmorduc O, Fartoux L. HCC and NASH: how strong is the 
clinical demonstration? Clin Res Hepatol Gastroenterol 2012; 36: 
202-208 [PMID: 22326764 DOI: 10.1016/j.clinre.2011.12.011]
15 Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty 
liver disease. Best Pract Res Clin Gastroenterol 2010; 24: 695-708 
[PMID: 20955971 DOI: 10.1016/j.bpg.2010.08.005]
16 Ciesla M, Skrzypek K, Kozakowska M, Loboda A, Jozkow-
icz A, Dulak J. MicroRNAs as biomarkers of disease onset. 
Anal Bioanal Chem 2011; 401: 2051-2061 [PMID: 21544542 
DOI: 10.1007/s00216-011-5001-8]
17 Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. MiR-122 in he-
patic function and liver diseases. Protein Cell 2012; 3: 364-371 
[PMID: 22610888 DOI: 10.1007/s13238-012-2036-3]
18 Carthew RW, Sontheimer EJ. Origins and Mechanisms of 
miRNAs and siRNAs. Cell 2009; 136: 642-655 [PMID: 19239886 
DOI: 10.1016/j.cell.2009.01.035]
19 Shenouda SK, Alahari SK. MicroRNA function in cancer: on-
cogene or a tumor suppressor? Cancer Metastasis Rev 2009; 28: 
369-378 [PMID: 20012925 DOI: 10.1007/s10555-009-9188-5]
20 Kerr TA, Korenblat KM, Davidson NO. MicroRNAs and 
liver disease. Transl Res 2011; 157: 241-252 [PMID: 21420035 
DOI: 10.1016/j.trsl.2011.01.008]
21 Lakner AM, Bonkovsky HL, Schrum LW. microRNAs: 
fad or future of liver disease. World J Gastroenterol 2011; 17: 
2536-2542 [PMID: 21633658 DOI: 10.3748/wjg.v17.i20.2536]
22 Borel F, Konstantinova P, Jansen PL. Diagnostic and thera-
peutic potential of miRNA signatures in patients with he-
patocellular carcinoma. J Hepatol 2012; 56: 1371-1383 [PMID: 
22314424 DOI: 10.1016/j.jhep.2011.11.026]
23 Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, Zeuzem 
S, Kronenberger B, Piiper A. Serum microRNA-122 levels in 
different groups of patients with chronic hepatitis B virus 
infection. J Viral Hepat 2012; 19: e58-e65 [PMID: 22239527 
DOI: 10.1111/j.1365-2893.2011.01536.x]
24 Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, 
Hoffer BA, Icardi MS, Christensen RN, Schmidt WN, Mc-
Caffrey AP. Correlation between microRNA expression lev-
els and clinical parameters associated with chronic hepatitis 
C viral infection in humans. Lab Invest 2010; 90: 1727-1736 
[PMID: 20625373 DOI: 10.1038/labinvest.2010.126]
25 Dávalos A, Goedeke L, Smibert P, Ramírez CM, Warrier 
NP, Andreo U, Cirera-Salinas D, Rayner K, Suresh U, Pas-
tor-Pareja JC, Esplugues E, Fisher EA, Penalva LO, Moore 
KJ, Suárez Y, Lai EC, Fernández-Hernando C. miR-33a/b 
contribute to the regulation of fatty acid metabolism and in-
sulin signaling. Proc Natl Acad Sci USA 2011; 108: 9232-9237 
[PMID: 21576456 DOI: 10.1073/pnas.1102281108]
26 Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda 
K, Kawada N. MicroRNA-221/222 upregulation indicates 
the activation of stellate cells and the progression of liver 
fibrosis. Gut 2012; 61: 1600-1609 [PMID: 22267590]
27 Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopou-
lou A, Polymeneas G, Voros D. Expression of microRNAs, 
miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, 
miR-221, miR-222, and miR-223 in patients with hepatocel-
lular carcinoma or intrahepatic cholangiocarcinoma and its 
prognostic significance. Mol Carcinog 2013; 52: 297-303 [PMID: 
22213236 DOI: 10.1002/mc.21864]
28 Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat 
F, Denk H, Desmet V, Korb G, MacSween RN. Histological 
grading and staging of chronic hepatitis. J Hepatol 1995; 22: 
696-699 [PMID: 7560864]
29 Doleshal M, Magotra AA, Choudhury B, Cannon BD, 
Labourier E, Szafranska AE. Evaluation and validation of 
total RNA extraction methods for microRNA expression 
analyses in formalin-fixed, paraffin-embedded tissues. J 
Mol Diagn 2008; 10: 203-211 [PMID: 18403610 DOI: 10.2353/
jmoldx.2008.070153]
30 Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-
time quantitative reverse transcription-PCR data: a model-
based variance estimation approach to identify genes suited 
for normalization, applied to bladder and colon cancer data 
sets. Cancer Res 2004; 64: 5245-5250 [PMID: 15289330]
31 Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsu-
ura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Bréchot 
C. Hepatitis C virus core protein shows a cytoplasmic local-
ization and associates to cellular lipid storage droplets. Proc 
Natl Acad Sci USA 1997; 94: 1200-1205 [PMID: 9037030]
32 Ratziu V, Trabut JB, Poynard T. Fat, diabetes, and liver 
injury in chronic hepatitis C. Curr Gastroenterol Rep 2004; 6: 
22-29 [PMID: 14720450]
33 Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Ste-
atosis in chronic hepatitis C: relative contributions of obesity, 
diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-736 
[PMID: 12198667]
34 Cross TJ, Rashid MM, Berry PA, Harrison PM. The impor-
tance of steatosis in chronic hepatitis C infection and its 
management: A review. Hepatol Res 2010; 40: 237-247 [PMID: 
20394672]
35 Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely 
RD. Lipids and HCV. Semin Immunopathol 2013; 35: 87-100 
[PMID: 23111699 DOI: 10.1007/s00281-012-0356-2]
36 Cirera-Salinas D, Pauta M, Allen RM, Salerno AG, Ramírez 
CM, Chamorro-Jorganes A, Wanschel AC, Lasuncion MA, 
Morales-Ruiz M, Suarez Y, Baldan Á, Esplugues E, Fernán-
dez-Hernando C. Mir-33 regulates cell proliferation and 
cell cycle progression. Cell Cycle 2012; 11: 922-933 [PMID: 
22333591 DOI: 10.4161/cc.11.5.19421]
37 Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel 
W, Tuschl T. Identification of tissue-specific microRNAs 
from mouse. Curr Biol 2002; 12: 735-739 [PMID: 12007417]
38 Ding X, Ding J, Ning J, Yi F, Chen J, Zhao D, Zheng J, Liang 
Z, Hu Z, Du Q. Circulating microRNA-122 as a potential 
biomarker for liver injury. Mol Med Rep 2012; 5: 1428-1432 
[PMID: 22427142 DOI: 10.3892/mmr.2012.838]
39 Shimakami T, Yamane D, Jangra RK, Kempf BJ, Spaniel C, 
Barton DJ, Lemon SM. Stabilization of hepatitis C virus RNA 
by an Ago2-miR-122 complex. Proc Natl Acad Sci USA 2012; 
109: 941-946 [PMID: 22215596 DOI: 10.1073/pnas.1112263109]
15349 November 7, 2014|Volume 20|Issue 41|WJG|www.wjgnet.com
Lendvai G et al . microRNA expression in chronic HCV
40 Sarasin-Filipowicz M. Interferon therapy of hepatitis C: 
molecular insights into success and failure. Swiss Med Wkly 
2010; 140: 3-11 [PMID: 19950038]
41 Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, 
D’Onorio de Meo P, Cervello M, Montalto G, Pollicino T, 
Raimondo G, Levrero M, Pediconi N. Transcriptional regu-
lation of miR-224 upregulated in human HCCs by NFκB 
inflammatory pathways. J Hepatol 2012; 56: 855-861 [PMID: 
22178270 DOI: 10.1016/j.jhep.2011.11.017]
42 Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, 
Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. 
miR-221 overexpression contributes to liver tumorigenesis. 
Proc Natl Acad Sci USA 2010; 107: 264-269 [PMID: 20018759 
DOI: 10.1073/pnas.0907904107]
43 Ma D, Tao X, Gao F, Fan C, Wu D. miR-224 functions as an 
onco-miRNA in hepatocellular carcinoma cells by activating 
AKT signaling. Oncol Lett 2012; 4: 483-488 [PMID: 23741247]
44 Tryndyak VP, Latendresse JR, Montgomery B, Ross SA, 
Beland FA, Rusyn I, Pogribny IP. Plasma microRNAs are 
sensitive indicators of inter-strain differences in the sever-
ity of liver injury induced in mice by a choline- and folate-
deficient diet. Toxicol Appl Pharmacol 2012; 262: 52-59 [PMID: 
22561871 DOI: 10.1016/j.taap.2012.04.018]
45 Bao L, Yan Y, Xu C, Ji W, Shen S, Xu G, Zeng Y, Sun B, Qian 
H, Chen L, Wu M, Su C, Chen J. MicroRNA-21 suppresses 
PTEN and hSulf-1 expression and promotes hepatocellular 
carcinoma progression through AKT/ERK pathways. Can-
cer Lett 2013; 337: 226-236 [PMID: 23684551 DOI: 10.1016/
j.canlet.2013.05.007]
46 Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt 
L, Buhler LH, Foti M. Unsaturated fatty acids inhibit the 
expression of tumor suppressor phosphatase and tensin 
homolog (PTEN) via microRNA-21 up-regulation in hepato-
cytes. Hepatology 2009; 49: 1176-1184 [PMID: 19072831 DOI: 
10.1002/hep.22737]
47 Li S, Chen X, Zhang H, Liang X, Xiang Y, Yu C, Zen K, Li Y, 
Zhang CY. Differential expression of microRNAs in mouse liv-
er under aberrant energy metabolic status. J Lipid Res 2009; 50: 
1756-1765 [PMID: 19372595 DOI: 10.1194/jlr.M800509-JLR200]
48 Zheng L, Lv GC, Sheng J, Yang YD. Effect of miRNA-10b 
in regulating cellular steatosis level by targeting PPAR-
alpha expression, a novel mechanism for the pathogenesis 
of NAFLD. J Gastroenterol Hepatol 2010; 25: 156-163 [PMID: 
19780876 DOI: 10.1111/j.1440-1746.2009.05949.x]
P- Reviewer: Osna NA    S- Editor: Ma YJ 
L- Editor: A    E- Editor: Liu XM
15350 November 7, 2014|Volume 20|Issue 41|WJG|www.wjgnet.com
Lendvai G et al . microRNA expression in chronic HCV
